Pharmacosmos A/S
Trilaciclib
Limited Stage Small Cell Lung Cancer
Countdown
358days
Phase 3 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 3 trial results for Trilaciclib in Limited Stage Small Cell Lung Cancer are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT07473128: Phase 3 trial, sponsor Pharmacosmos A/S, drug Trilaciclib. Primary completion date 2027-06 (estimated).”